Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
American Journal of Hematology · 2025-02 · 100 (2) · 236-248
DOI: 10.1002/ajh.27548 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 23.12.2024. Verfasst von Swetha Kambhampati Thiruvengadam und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Schwartz Accelerator Funds, American Society of Hematology.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment of aggressive large B‐cell lymphoma (aLBCL). Patients with transformed indolent non‐Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR for this distinct, historically high‐risk group are poorly understood. We conducted a multicenter retrospective study of 1182 patients with aLBCL receiving standard‐of‐care CAR T between 2017 and 2022, including 338 (29%) with tiNHL. Rates of grade ≥ 3 cytokine release syndrome (CRS) were similar between tiNHL and de novo cohorts (7% vs. 8%, p = 0.6), while grade ≥ 3 immune effector cell‐associated neurotoxicity syndrome was lower in tiNHL (21% vs. 27%, p = 0.02). Overall response rate was similar in both cohorts (83% vs. 81%, p = 0.3), while complete response rate was higher in tiNHL (67% vs. 59%, p = 0.017). With a median follow‐up of 22.3 months, the progression/relapse‐free (PFS) and overall survival (OS) were similar between the tiNHL and de novo cohorts (24‐month PFS 41% [95% CI: 35%–46%] vs. 38% [95% CI: 35%–42%]; 24‐month OS 58% [95% CI: 52%–63%] vs. 52% [95% CI: 48%–56%], respectively). After adjusting for key risk factors, there was a trend toward a lower hazard of disease progression, relapse or death post‐CAR for tiNHL patients compared to de novo aLBCL patients (HR: 0.84 [95% CI: 0.69–1.0], p = 0.07). Elevated LDH, advanced stage, prior bendamustine within 12 months of CAR, receipt of bridging therapy, CNS involvement, and ≥ 3 prior lines of therapy were each associated with inferior PFS. In conclusion, CAR T therapy is highly effective with an acceptable toxicity profile in patients with tiNHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.
- Department of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope National Medical Center, Duarte, California, USA.
- Department of Lymphoma-Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas, USA.
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA.
- Division of Hematology and Oncology, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Swetha Kambhampati Thiruvengadam, Yan Wang, Alma Habib, Adam S Kittai, Lihua E Budde
Förderung
- NCI NIH HHS
- Schwartz Accelerator Funds
- American Society of Hematology
- National Cancer Institute/NIH
Zitieren
APA
Thiruvengadam, S. K., Merryman, R., Wang, Y., Gaulin, C., Bezerra, E., Voorhees, T., Seshadri, M. R., Falade, A., Habib, A., Ayers, A. A., Bailey, M., Brown, A., Bailey, N., Patel, K., Andreadis, C. B., Kittai, A. S., Jacobson, C., Palmer, J., Forman, S. J., …, & Budde, L. E. (2025). Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma. American Journal of Hematology, 100(2), 236-248. https://doi.org/10.1002/ajh.27548
Vancouver
Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, et al. Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma. American Journal of Hematology. 2025;100(2):236-248. doi:10.1002/ajh.27548
BibTeX
@article{Thiruvengadam2025,
author = {Thiruvengadam, Swetha Kambhampati and Merryman, Reid and Wang, Yan and Gaulin, Charles and Bezerra, Evandro and Voorhees, Timothy and Seshadri, Madhav R and Falade, Ayo and Habib, Alma and Ayers, Amy A and Bailey, Megumi and Brown, Annette and Bailey, Neil and Patel, Krish and Andreadis, Charalambos B and Kittai, Adam S and Jacobson, Caron and Palmer, Joycelynne and Forman, Stephen J and Nastoupil, Loretta and Budde, Lihua E},
title = {Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {2},
pages = {236--248},
doi = {10.1002/ajh.27548}
}
EUVIMED